MXI1
Expression of the c-myc gene, which produces an oncogenic transcription factor, is tightly regulated in normal cells but is frequently deregulated in human cancers. The protein encoded by this gene is a transcriptional repressor thought to negatively regulate MYC function, and is therefore a potential tumor suppressor. This protein inhibits the transcriptional activity of MYC by competing for MAX, another basic helix-loop-helix protein that binds to MYC and is required for its function. Defects in this gene are frequently found in patients with prostate tumors. Three alternatively spliced transcripts encoding different isoforms have been described. Additional alternatively spliced transcripts may exist but the products of these transcripts have not been verified experimentally. [provided by RefSeq]
                Full Name
                    MXI1
                Function
                    Transcriptional repressor. MXI1 binds with MAX to form a sequence-specific DNA-binding protein complex which recognizes the core sequence 5'-CAC[GA]TG-3'. MXI1 thus antagonizes MYC transcriptional activity by competing for MAX.
                Biological Process
                    Negative regulation of transcription by RNA polymerase II Source: NTNU_SB
Regulation of transcription by RNA polymerase II Source: GO_Central
                Regulation of transcription by RNA polymerase II Source: GO_Central
Cellular Location
                    Nucleus
                Involvement in disease
                    Prostate cancer (PC):
A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.
                A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.
                            View more
                        
   
                    Anti-MXI1 antibodies
 + Filters
		
Loading...
        Target: MXI1
                
                Host: Mouse
                
                Antibody Isotype: IgG2b
                
                Specificity: Human
                
                Clone: 1A3
                
                Application*: IP, WB, M
                
            Target: MXI1
                
                Host: Mouse
                
                Antibody Isotype: IgG2a, κ
                
                Specificity: Human
                
                Clone: CBFYM-2863
                
                Application*: E, WB
                
            Target: MXI1
                
                Host: Mouse
                
                Antibody Isotype: IgG2a, κ
                
                Specificity: Human
                
                Clone: CBFYM-2862
                
                Application*: E, IF, WB
                
            Target: MXI1
                
                Host: Mouse
                
                Antibody Isotype: IgG1
                
                Specificity: Human
                
                Clone: CBFYM-2861
                
                Application*: DB, WB
                
            More Infomation
Hot products 
    - 
            Mouse Anti-ACTN4 Recombinant Antibody (V2-6075) (CBMAB-0020CQ)
             - 
            Mouse Anti-ALB Recombinant Antibody (V2-180650) (CBMAB-A2186-YC)
             - 
            Human Anti-SARS-CoV-2 S1 Monoclonal Antibody (CBFYR-0120) (CBMAB-R0120-FY)
             - 
            Mouse Anti-ATP1A2 Recombinant Antibody (M7-PB-E9) (CBMAB-A4013-YC)
             - 
            Mouse Anti-ESR1 Recombinant Antibody (Y31) (CBMAB-1208-YC)
             - 
            Mouse Anti-ADV Recombinant Antibody (V2-503423) (CBMAB-V208-1364-FY)
             - 
            Mouse Anti-ACTB Recombinant Antibody (V2-179553) (CBMAB-A0870-YC)
             - 
            Mouse Anti-ALB Recombinant Antibody (V2-363290) (CBMAB-S0173-CQ)
             - 
            Mouse Anti-DLG1 Monolconal Antibody (4F3) (CBMAB-0225-CN)
             - 
            Mouse Anti-BHMT Recombinant Antibody (CBYY-0547) (CBMAB-0550-YY)
             - 
            Rabbit Anti-ATF4 Recombinant Antibody (D4B8) (CBMAB-A3872-YC)
             - 
            Mouse Anti-CASQ1 Recombinant Antibody (CBFYC-0863) (CBMAB-C0918-FY)
             - 
            Mouse Anti-CIITA Recombinant Antibody (CBLC160-LY) (CBMAB-C10987-LY)
             - 
            Mouse Anti-APP Recombinant Antibody (DE2B4) (CBMAB-1122-CN)
             - 
            Mouse Anti-C5b-9 Recombinant Antibody (aE11) (CBMAB-AO138LY)
             - 
            Mouse Anti-ALOX5 Recombinant Antibody (33) (CBMAB-1890CQ)
             - 
            Mouse Anti-ALDOA Recombinant Antibody (A2) (CBMAB-A2316-YC)
             - 
            Mouse Anti-ADRB2 Recombinant Antibody (V2-180026) (CBMAB-A1420-YC)
             - 
            Mouse Anti-AHCYL1 Recombinant Antibody (V2-180270) (CBMAB-A1703-YC)
             - 
            Mouse Anti-CD33 Recombinant Antibody (P67.6) (CBMAB-C10189-LY)
             
For Research Use Only. Not For Clinical Use.
                    (P): Predicted
* Abbreviations 
- AActivation
 - AGAgonist
 - APApoptosis
 - BBlocking
 - BABioassay
 - BIBioimaging
 - CImmunohistochemistry-Frozen Sections
 - CIChromatin Immunoprecipitation
 - CTCytotoxicity
 - CSCostimulation
 - DDepletion
 - DBDot Blot
 
- EELISA
 - ECELISA(Cap)
 - EDELISA(Det)
 - ESELISpot
 - EMElectron Microscopy
 - FFlow Cytometry
 - FNFunction Assay
 - GSGel Supershift
 - IInhibition
 - IAEnzyme Immunoassay
 - ICImmunocytochemistry
 - IDImmunodiffusion
 - IEImmunoelectrophoresis
 
- IFImmunofluorescence
 - IGImmunochromatography
 - IHImmunohistochemistry
 - IMImmunomicroscopy
 - IOImmunoassay
 - IPImmunoprecipitation
 - ISIntracellular Staining for Flow Cytometry
 - LALuminex Assay
 - LFLateral Flow Immunoassay
 - MMicroarray
 - MCMass Cytometry/CyTOF
 - MDMeDIP
 
- MSElectrophoretic Mobility Shift Assay
 - NNeutralization
 - PImmunohistologyp-Paraffin Sections
 - PAPeptide Array
 - PEPeptide ELISA
 - PLProximity Ligation Assay
 - RRadioimmunoassay
 - SStimulation
 - SESandwich ELISA
 - SHIn situ hybridization
 - TCTissue Culture
 - WBWestern Blot
 
                Online Inquiry
                
    
           
        
        


